Wokingham, England, July 22, 2010 (ots/PRNewswire) - Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory Authority (MHRA) acting as the Reference Member State for 16 EU countries. Pitavastatin is indicated for the reduction ...
Wokingham, England, June 28, 2010 (ots/PRNewswire) - Following an enthusiastic expansion programme into new markets, Kowa Company, Ltd. (President: Yoshihiro Miwa), headquartered in Nagoya, Japan, has granted Abbott, headquartered in Illinois, USA the exclusive license to distribute and market pitavastatin ...
Wokingham, England, April 28, 2010 (ots/PRNewswire) - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP* and EAS* low-density lipoprotein ...
Barcelona, Spain (ots/PRNewswire) - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant ...
Barcelona, Spain (ots/PRNewswire) - - Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to ...